Abstract Number: PB0013
Meeting: ISTH 2020 Congress
Background: Exosomes (EXOs), a subgroup of extracellular vesicles, are important mediators of inter-cellular communication. They reflect the physio-pathological state of the parental cell, suggesting their potential as diagnostic and prognostic tool in pathological conditions. The signature and the implication of EXOs in ST‐elevation acute myocardial infarction (STEMI) are still partially unknown.
Aims: This study is aimed at identifying the potential differences in EXOs profile between STEMI and stable coronary artery disease (CAD).
Methods: EXOs were isolated from plasma of STEMI (at hospital admission; n=18) and CAD (absence of acute coronary symptoms from at least 12 months; n=31) male patients using commercial kits. EXOs were validated by analyzing the morphology (transmission electron microscopy) and the expression of specific exosome markers (western blot, WB). Concentration and size distribution were determined by Nanoparticle Tracking Analysis and protein cargo screened by proteomic approach and confirmed by WB. The study complies with Declaration of Helsinki and was approved by the Centro Cardiologico Monzino Ethical Committee. All patients provided written informed consent.
Results: EXOs from STEMI patients displayed a higher concentration (p=0.0012) and mode (p=0.0005) compared to CAD patients. The greater expression of the platelet marker CD41 (p=0.0007) in STEMI patients suggests an important platelet contribution to circulating EXOs in these patients. By proteomic analysis, we identified about 20 proteins differentially expressed in STEMI- and CAD-EXOs which are mainly involved in inflammation, integrin signaling pathway and blood coagulation. Some of these proteins have been previously recognized as independent predictor of major adverse cardiac events in patients with acute myocardial infarction (AMI) and associated with increased long-term mortality after AMI.
Conclusions: The pronounced differences emerged between plasma EXOs of STEMI and CAD patients provide evidence that EXO signature reflects the clinical manifestation, suggesting their potential application in clinical practice. Larger studies are required to confirm these data.
To cite this abstract in AMA style:Zarà M, Campodonico J, Cosentino N, Biondi ML, Milanesi G, Brioschi M, Assanelli EM, Cerri S, Banfi C, Amadio P, Biggiogera M, Sandrini L, Trabattoni D, Terzaghi M, Blandini F, Tremoli E, Marenzi G, Barbieri SS. Plasma Exosomes in Patients with ST‐Elevation Acute Myocardial Infarction (STEMI) and in Patients with Stable Coronary Artery Disease (CAD) [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/plasma-exosomes-in-patients-with-st%e2%80%90elevation-acute-myocardial-infarction-stemi-and-in-patients-with-stable-coronary-artery-disease-cad/. Accessed January 28, 2022.
« Back to ISTH 2020 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/plasma-exosomes-in-patients-with-st%e2%80%90elevation-acute-myocardial-infarction-stemi-and-in-patients-with-stable-coronary-artery-disease-cad/